CompletedNot Applicable

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura

China59 participantsStarted 2020-06-14

Plain-language summary

The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with Henoch-schönlein purpura.

Age range17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. heart failure (cardiac function ≥ grade III NYHA)
✕. liver insufficiency (upper limit of normal range of transaminase \> 2 times)
✕. renal insufficiency (creatinine clearance ≤30ml/min)
✕. acute or severe infections such as bacteremia and sepsis
✕. malignant tumor
✕. high-dose steroid pulse therapy or intravenous injection of glucocorticoids in the last 1 month
✕. mental disorders or any other chronic illness or substance abuse may interfere with the ability to comply with agreements or provide information
✕. Intestinal ischemia or perforated gastrointestinal bleeding requires surgery

The change of immunological responses

Timeframe: day 0,day 7

NCT IDNCT04387942

SponsorThe First Hospital of Jilin University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-31